During the past decade, HitGen Inc. conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "HitGen Inc." are "Advanced Solid Tumor" (1 trials), "Multiple Myeloma" (1 trials) and "Relapsed and Refractory Multiple Myeloma" (1 trials). Many other conditions were trialed in "HitGen Inc." in a lesser frequency.

Most popular intervention types in "HitGen Inc." are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "HG146" (1 trials) and "HG381" (1 trials). Other intervention names were less common.

The vast majority of trials in "HitGen Inc." are 2 trials for "All" genders.

Currently, there are NaN active trials in "HitGen Inc.". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in HitGen Inc., undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in HitGen Inc., 2 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".